CellSeed

CellSeed Receivables

The Accounts Receivable of CellSeed (7776.T) as of Oct 27, 2026 is 37.13 M JPY. In the previous year, Accounts Receivable was 51.87 M JPY — a change of -28.43% (lower).

Receivables

37.13 MJPY

YoY

-28.43%

Last updated:

Accounts Receivable of CellSeed is 2024 37.13 M JPY. Accounts Receivable of CellSeed was 2023 51.87 M JPY. It decreases by -28.43% lower compared to the previous year.

The CellSeed Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
34.63 M JPY
Jan 1, 2018
328.46 M JPY
Jan 1, 2019
56.56 M JPY
Jan 1, 2020
45.88 M JPY
Jan 1, 2021
28.16 M JPY
Jan 1, 2022
25.78 M JPY
Jan 1, 2023
51.87 M JPY
Jan 1, 2024
37.13 M JPY
The CellSeed Receivables history
YEARReceivablesYoY
37.13 MJPY-28.43%
51.87 MJPY+101.25%
25.78 MJPY-8.48%
28.16 MJPY-38.61%
45.88 MJPY-18.89%
56.56 MJPY-82.78%
328.46 MJPY+848.36%
34.63 MJPY-42.07%
59.79 MJPY+123.37%
26.77 MJPY+45.91%
18.35 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Accounts Receivable of CellSeed is 37.13 M JPY in 2024.

Accounts Receivable of CellSeed changed from 51.87 M JPY to 37.13 M JPY, representing a -28.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable CellSeed since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's CellSeed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CellSeed

All Key Metrics — CellSeed